{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:36:24Z","timestamp":1793914584966,"version":"4.8.0"},"reference-count":121,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T00:00:00Z","timestamp":1608681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000850","name":"National Heart and Lung Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000850","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Alpha2-antiplasmin (\u03b12AP), the fast-reacting, serine protease inhibitor (serpin) of plasmin, was originally thought to play a key role in protection against uncontrolled, plasmin-mediated proteolysis of coagulation factors and other molecules. However, studies of humans and mice with genetic deficiency of \u03b12AP have expanded our understanding of this serpin, particularly in disease states. Epidemiology studies have shown an association between high \u03b12AP levels and increased risk or poor outcome in cardiovascular diseases. Mechanistic studies in disease models indicate that \u03b12AP stops the body's own fibrinolytic system from dissolving pathologic thrombi that cause venous thrombosis, pulmonary embolism, arterial thrombosis, and ischemic stroke. In addition, \u03b12AP fosters the development of microvascular thrombosis and enhances matrix metalloproteinase-9 expression. Through these mechanisms and others, \u03b12AP contributes to brain injury, hemorrhage and swelling in experimental ischemic stroke. Recent studies also show that \u03b12AP is required for the development of stasis thrombosis by inhibiting the early activation of effective fibrinolysis. In this review, we will discuss the key role played by \u03b12AP in controlling thrombosis and fibrinolysis and, we will consider its potential value as a therapeutic target in cardiovascular diseases and ischemic stroke.<\/jats:p>","DOI":"10.3389\/fcvm.2020.608899","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T04:24:11Z","timestamp":1608697451000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":62,"title":["Alpha2-Antiplasmin: The Devil You Don't Know in Cerebrovascular and Cardiovascular Disease"],"prefix":"10.3389","volume":"7","author":[{"given":"Satish","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofiyan","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy L.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/j.1432-1033.1978.tb12200.x","article-title":"On the kinetics of the reaction between human antiplasmin and plasmin","volume":"84","author":"Wiman","year":"1978","journal-title":"Eur J Biochem."},{"key":"B2","doi-asserted-by":"crossref","first-page":"9291","DOI":"10.1016\/S0021-9258(19)86843-6","article-title":"On the mechanism of the reaction between human alpha 2-antiplasmin and plasmin","volume":"254","author":"Wiman","year":"1979","journal-title":"J Biol Chem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1182\/blood.V51.4.563.563","article-title":"Fast-acting plasmin inhibitor in human plasma","volume":"51","author":"Collen","year":"1978","journal-title":"Blood."},{"key":"B4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1432-1033.1976.tb10875.x","article-title":"Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma","volume":"69","author":"Collen","year":"1976","journal-title":"Eur J Biochem"},{"key":"B5","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1016\/S0021-9258(17)33045-4","article-title":"Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis","volume":"251","author":"Moroi","year":"1976","journal-title":"J Biol Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1042\/bj1590545","article-title":"The primary inhibitor of plasmin in human plasma","volume":"159","author":"Mullertz","year":"1976","journal-title":"Biochem J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1538-7836.2004.01055.x","article-title":"Discovery of alpha2-plasmin inhibitor and its congenital deficiency","volume":"3","author":"Aoki","year":"2005","journal-title":"J Thromb Haemost"},{"key":"B8","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/jcp.34.9.979","article-title":"Concentration of plasminogen and antiplasmin in plasma and serum","volume":"34","author":"Cederholm-Williams","year":"1981","journal-title":"J Clin Pathol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nprot.2010.5","article-title":"I-TASSER: a unified platform for automated protein structure and function prediction","volume":"5","author":"Roy","year":"2010","journal-title":"Nat Protoc."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1182\/blood-2007-09-114215","article-title":"X-ray crystal structure of the fibrinolysis inhibitor alpha2-antiplasmin","volume":"111","author":"Law","year":"2008","journal-title":"Blood."},{"key":"B11","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/S0021-9258(19)75687-7","article-title":"Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin)","volume":"262","author":"Holmes","year":"1987","journal-title":"J Biol Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1042\/bj2910623","article-title":"Different N-terminal forms of alpha 2-plasmin inhibitor in human plasma","volume":"291","author":"Bangert","year":"1993","journal-title":"Biochem J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"24544","DOI":"10.1074\/jbc.M111.229013","article-title":"Contribution of conserved lysine residues in the alpha2-antiplasmin C terminus to plasmin binding and inhibition","volume":"286","author":"Lu","year":"2011","journal-title":"J Biol Chem."},{"key":"B14","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/0005-2744(77)90255-8","article-title":"On the interaction of alpha2-plasmin inhibitor and proteases. Evidence for the formation of a covalent crosslinkage and non-covalent weak bondings between the inhibitor and proteases","volume":"482","author":"Moroi","year":"1977","journal-title":"Biochim Biophys Acta."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1111\/j.1538-7836.2007.02652.x","article-title":"Fibrinolysis is amplified by converting alpha-antiplasmin from a plasmin inhibitor to a substrate","volume":"5","author":"Sazonova","year":"2007","journal-title":"J Thromb Haemost."},{"key":"B16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0049-3848(82)90029-9","article-title":"Synthesis of alpha 2-antiplasmin by rat liver cells","volume":"28","author":"Hogstorp","year":"1982","journal-title":"Thromb Res."},{"key":"B17","first-page":"372","article-title":"Synthesis and secretion of the fibrinolytic components, including alpha 2-antiplasmin, by a human hepatoma cell line","volume":"101","author":"Fair","year":"1983","journal-title":"J Lab Clin Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1182\/blood-2015-09-670117","article-title":"Natural heterogeneity of alpha2-antiplasmin: functional and clinical consequences","volume":"127","author":"Abdul","year":"2016","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1172\/JCI118694","article-title":"The kidney is a major site of alpha(2)-antiplasmin production","volume":"97","author":"Menoud","year":"1996","journal-title":"J Clin Invest."},{"key":"B20","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/j.1582-4934.2011.01394.x","article-title":"Activators and inhibitors of the plasminogen system in Alzheimer's disease","volume":"16","author":"Barker","year":"2012","journal-title":"J Cell Mol Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics: tissue-based map of the human proteome","volume":"347","author":"Uhlen","year":"2015","journal-title":"Science."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1055\/s-0038-1657694","article-title":"Characterization and targeting of the murine alpha2-antiplasmin gene","volume":"78","author":"Okada","year":"1997","journal-title":"Thromb Haemost."},{"key":"B23","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S1096-4959(01)00396-7","article-title":"Purification and partial characterisation of alpha(2)-antiplasmin and plasmin(ogen) from ostrich plasma","volume":"129","author":"Thomas","year":"2001","journal-title":"Comp Biochem Physiol B Biochem Mol Biol."},{"key":"B24","first-page":"65","article-title":"[Alpha 2-antiplasmin in bovine plasma]","volume":"57","author":"Piliavskaia","year":"1985","journal-title":"Ukr Biokhim Zh (1978)."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/oxfordjournals.jbchem.a122141","article-title":"Structure of human alpha 2-plasmin inhibitor deduced from the cDNA sequence","volume":"102","author":"Tone","year":"1987","journal-title":"J Biochem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1111\/j.1742-4658.2005.04881.x","article-title":"Antiplasmin. the forgotten serpin?","volume":"272","author":"Coughlin","year":"2005","journal-title":"FEBS J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/j.1432-1033.1994.00863.x","article-title":"Characterization of the murine plasma fibrinolytic system","volume":"224","author":"Lijnen","year":"1994","journal-title":"Eur J Biochem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1161\/CIRCULATIONAHA.116.024421","article-title":"Releasing the brakes on the fibrinolytic system in pulmonary emboli: unique effects of plasminogen activation and alpha2-antiplasmin inactivation","volume":"135","author":"Singh","year":"2017","journal-title":"Circulation."},{"key":"B29","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/0049-3848(84)90081-1","article-title":"The molecular form of alpha 2-antiplasmin with affinity for plasminogen is selectively bound to fibrin by factor XIII","volume":"33","author":"Kluft","year":"1984","journal-title":"Thromb Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1172\/JCI109671","article-title":"Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor","volume":"65","author":"Sakata","year":"1980","journal-title":"J Clin Invest."},{"key":"B31","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1172\/JCI110479","article-title":"Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis","volume":"69","author":"Sakata","year":"1982","journal-title":"J Clin Invest."},{"key":"B32","first-page":"21","article-title":"Fibrin-fibrin and alpha 2-antiplasmin-fibrin cross-linking by platelet factor XIII increases the resistance of platelet clots to fibrinolysis","volume":"104","author":"Reed","year":"1991","journal-title":"Trans Assoc Am Physicians."},{"key":"B33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1089\/hyb.1997.16.281","article-title":"Functional characterization of monoclonal antibody inhibitors of alpha 2-antiplasmin that accelerate fibrinolysis in different animal plasmas","volume":"16","author":"Reed","year":"1997","journal-title":"Hybridoma"},{"key":"B34","doi-asserted-by":"publisher","first-page":"6371","DOI":"10.1182\/blood-2011-02-333203","article-title":"The antifibrinolytic function of factor XIII is exclusively expressed through alpha(2)-antiplasmin cross-linking","volume":"117","author":"Fraser","year":"2011","journal-title":"Blood."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1209676","DOI":"10.1155\/2017\/1209676","article-title":"Inhibition of fibrinolysis by coagulation factor XIII","volume":"2017","author":"Rijken","year":"2017","journal-title":"Biomed Res Int."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1182\/blood-2003-12-4240","article-title":"A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion","volume":"103","author":"Lee","year":"2004","journal-title":"Blood."},{"key":"B37","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/0005-2795(79)90094-1","article-title":"On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen","volume":"579","author":"Wiman","year":"1979","journal-title":"Biochim Biophys Acta."},{"key":"B38","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1055\/s-0037-1615612","article-title":"Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin","volume":"85","author":"Lee","year":"2001","journal-title":"Thromb Haemost."},{"key":"B39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1042\/bj2710051","article-title":"The mechanism of activation of plasminogen at the fibrin surface by tissue-type plasminogen activator in a plasma milieu in vitro. Role of alpha 2-antiplasmin","volume":"271","author":"Rouy","year":"1990","journal-title":"Biochem J"},{"key":"B40","doi-asserted-by":"crossref","first-page":"12329","DOI":"10.1016\/S0021-9258(18)98900-3","article-title":"Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin","volume":"266","author":"Hall","year":"1991","journal-title":"J Biol Chem."},{"key":"B41","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1182\/blood.V100.3.743","article-title":"Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms","volume":"100","author":"Ariens","year":"2002","journal-title":"Blood."},{"key":"B42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/jth.12455","article-title":"The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis","volume":"12","author":"Hethershaw","year":"2014","journal-title":"J Thromb Haemost."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1111\/jth.13354","article-title":"Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII","volume":"14","author":"Rijken","year":"2016","journal-title":"J Thromb Haemost."},{"key":"B44","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1161\/01.CIR.99.2.299","article-title":"The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism","volume":"99","author":"Reed","year":"1999","journal-title":"Circulation."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1172\/JCI75386","article-title":"Factor XIII activity mediates red blood cell retention in venous thrombi","volume":"124","author":"Aleman","year":"2014","journal-title":"J Clin Invest."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1182\/blood-2015-06-652263","article-title":"Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin alpha-chain crosslinking","volume":"126","author":"Byrnes","year":"2015","journal-title":"Blood."},{"key":"B47","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/j.1538-7836.2007.02430.x","article-title":"complementary roles in regulating lysis of thrombi and plasma clots","volume":"5","year":"2007","journal-title":"J Thromb Haemost."},{"key":"B48","doi-asserted-by":"publisher","first-page":"d556","DOI":"10.2741\/A794","article-title":"Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice","volume":"7","author":"Nagashima","year":"2002","journal-title":"Front Biosci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1111\/jth.12036","article-title":"The hyperfibrinolytic state of mice with combined thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 gene deficiency is critically dependent on TAFI deficiency","volume":"10","author":"Vercauteren","year":"2012","journal-title":"J Thromb Haemost."},{"key":"B50","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1055\/s-0037-1616099","article-title":"Enhanced fibrinolytic potential in mice with combined homozygous deficiency of alpha2-antiplasmin and PAI-1","volume":"86","author":"Dewerchin","year":"2001","journal-title":"Thromb Haemost."},{"key":"B51","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41572-019-0118-8","article-title":"Ischaemic stroke","volume":"5","author":"Campbell","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"B52","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1159\/000297966","article-title":"Novel hemostatic factor levels and risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"29","author":"Suri","year":"2010","journal-title":"Cerebrovasc Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1212\/01.wnl.0000171704.50395.ba","article-title":"Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA","volume":"65","author":"Marti-Fabregas","year":"2005","journal-title":"Neurology."},{"key":"B54","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1055\/s-0036-1585077","article-title":"alpha2-antiplasmin: new insights and opportunities for ischemic stroke","volume":"43","author":"Reed","year":"2017","journal-title":"Semin Thromb Hemost."},{"key":"B55","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.expneurol.2014.02.009","article-title":"Reversing the deleterious effects of alpha2-antiplasmin on tissue plasminogen activator therapy improves outcomes in experimental ischemic stroke","volume":"255","author":"Houng","year":"2014","journal-title":"Exp Neurol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1161\/ATVBAHA.114.304530","article-title":"Microvascular thrombosis, fibrinolysis, ischemic injury, and death after cerebral thromboembolism are affected by levels of circulating alpha2-antiplasmin","volume":"34","author":"Reed","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1161\/01.CIR.99.18.2440","article-title":"Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice","volume":"99","author":"Nagai","year":"1999","journal-title":"Circulation."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1182\/blood.V97.10.3086","article-title":"Depletion of circulating alpha(2)-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization","volume":"97","author":"Nagai","year":"2001","journal-title":"Blood."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1161\/ATVBAHA.114.304616","article-title":"alpha2 Antiplasmin and microvascular thrombosis in ischemic stroke","volume":"34","author":"Su","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1161\/01.CIR.95.7.1886","article-title":"Alpha 2-antiplasmin causes thrombi to resist fibrinolysis induced by tissue plasminogen activator in experimental pulmonary embolism","volume":"95","author":"Butte","year":"1997","journal-title":"Circulation."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1182\/blood.V93.7.2274","article-title":"Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding","volume":"93","author":"Lijnen","year":"1999","journal-title":"Blood."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1073\/pnas.87.3.1114","article-title":"Synergistic fibrinolysis: combined effects of plasminogen activators and an antibody that inhibits alpha 2-antiplasmin","volume":"87","author":"Reed","year":"1990","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B63","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1055\/s-0037-1612950","article-title":"Plasmin generation plays different roles in the formation and removal of arterial and venous thrombus in mice","volume":"87","author":"Matsuno","year":"2002","journal-title":"Thromb Haemost."},{"key":"B64","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1182\/blood.2019000049","article-title":"Venous stasis-induced fibrinolysis prevents thrombosis in mice: role of alpha2-antiplasmin","volume":"134","author":"Singh","year":"2019","journal-title":"Blood."},{"key":"B65","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1182\/blood-2003-03-0700","article-title":"Lack of alpha: 2-antiplasmin promotes re-endothelialization via over-release of VEGF after vascular injury in mice","volume":"102","author":"Matsuno","year":"2003","journal-title":"Blood."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1182\/blood-2001-12-0251","article-title":"Lack of alpha2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction","volume":"100","author":"Matsuno","year":"2002","journal-title":"Blood."},{"key":"B67","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.neuroscience.2017.12.021","article-title":"Matrix metalloproteinase-9 mediates the deleterious effects of alpha2-antiplasmin on blood-brain barrier breakdown and ischemic brain injury in experimental stroke","volume":"376","author":"Singh","year":"2018","journal-title":"Neuroscience."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1111\/j.1538-7836.2004.00889.x","article-title":"Comparative effects of microplasmin and tissue-type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice","volume":"2","author":"Suzuki","year":"2004","journal-title":"J Thromb Haemost."},{"key":"B69","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1148\/radiol.2442061316","article-title":"Microplasmin and tissue plasminogen activator: comparison of therapeutic effects in rat stroke model at multiparametric MR imaging","volume":"244","author":"Chen","year":"2007","journal-title":"Radiology."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.3389\/fimmu.2019.01348","article-title":"Fibrinolysis and inflammation in venous thrombus resolution","volume":"10","author":"Mukhopadhyay","year":"2019","journal-title":"Front Immunol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1161\/01.CIR.82.1.164","article-title":"Inhibition of clot-bound alpha 2-antiplasmin enhances in vivo thrombolysis","volume":"82","author":"Reed","year":"1990","journal-title":"Circulation."},{"key":"B72","doi-asserted-by":"publisher","first-page":"18028","DOI":"10.1038\/nrdp.2018.28","article-title":"Pulmonary embolism","volume":"4","author":"Huisman","year":"2018","journal-title":"Nat Rev Dis Primers."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1046\/j.1538-7836.2003.00252.x","article-title":"Alpha2-antiplasmin plays a significant role in acute pulmonary embolism","volume":"1","author":"Matsuno","year":"2003","journal-title":"J Thromb Haemost."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1161\/01.ATV.20.6.1488","article-title":"Alpha(2)-antiplasmin gene deficiency in mice does not affect neointima formation after vascular injury","volume":"20","author":"Lijnen","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1161\/ATVBAHA.108.165688","article-title":"Alpha2-antiplasmin is a critical regulator of angiotensin II-mediated vascular remodeling","volume":"28","author":"Hou","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41572-019-0090-3","article-title":"ST-segment elevation myocardial infarction","volume":"5","author":"Vogel","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"B77","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/ame2.12010","article-title":"To develop a novel animal model of myocardial infarction: a research imperative","volume":"1","author":"Tang","year":"2018","journal-title":"Animal Model Exp Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12185-009-0476-1","article-title":"Pathophysiology of thrombotic thrombocytopenic purpura","volume":"91","author":"Tsai","year":"2010","journal-title":"Int J Hematol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1111\/jth.13859","article-title":"Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice","volume":"15","author":"Tersteeg","year":"2017","journal-title":"J Thromb Haemost."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1111\/j.1538-7836.2007.02745.x","article-title":"Alpha2-antiplasmin is involved in the production of transforming growth factor beta1 and fibrosis","volume":"5","author":"Kanno","year":"2007","journal-title":"J Thromb Haemost."},{"key":"B81","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/art.37767","article-title":"Alpha2-antiplasmin regulates the development of dermal fibrosis in mice by prostaglandin F(2alpha) synthesis through adipose triglyceride lipase\/calcium-independent phospholipase A(2)","volume":"65","author":"Kanno","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B82","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/08977194.2017.1349765","article-title":"The fibrinolysis inhibitor alpha2-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer","volume":"35","author":"Paquet-Fifield","year":"2017","journal-title":"Growth Factors."},{"key":"B83","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/jnc.12281","article-title":"Involvement of alpha2-antiplasmin in dendritic growth of hippocampal neurons","volume":"126","author":"Kawashita","year":"2013","journal-title":"J Neurochem."},{"key":"B84","doi-asserted-by":"publisher","first-page":"5967","DOI":"10.1038\/srep05967","article-title":"alpha2AP mediated myofibroblast formation and the development of renal fibrosis in unilateral ureteral obstruction","volume":"4","author":"Kanno","year":"2014","journal-title":"Sci Rep."},{"key":"B85","doi-asserted-by":"publisher","first-page":"e97947","DOI":"10.1371\/journal.pone.0097947","article-title":"Altered behavior in mice with deletion of the alpha2-antiplasmin gene","volume":"9","author":"Kawashita","year":"2014","journal-title":"PLoS One."},{"key":"B86","doi-asserted-by":"publisher","first-page":"E9687","DOI":"10.1073\/pnas.1811172115","article-title":"Blood-derived plasminogen drives brain inflammation and plaque deposition in a mouse model of Alzheimer's disease","volume":"115","author":"Baker","year":"2018","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1111\/j.1538-7836.2006.01978.x","article-title":"Lack of alpha2-antiplasmin improves cutaneous wound healing via over-released vascular endothelial growth factor-induced angiogenesis in wound lesions","volume":"4","author":"Kanno","year":"2006","journal-title":"J Thromb Haemost."},{"key":"B88","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jhep.2003.09.016","article-title":"The regulation of liver regeneration by the plasmin\/alpha 2-antiplasmin system","volume":"40","author":"Okada","year":"2004","journal-title":"J Hepatol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/S0140-6736(78)91973-6","article-title":"Alpha2-plasmin-inhibitor deficiency (Miyasato disease)","volume":"2","author":"Koie","year":"1978","journal-title":"Lancet."},{"key":"B90","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1172\/JCI109387","article-title":"Congenital deficiency of alpha 2-plasmin inhibitor associated with severe hemorrhagic tendency","volume":"63","author":"Aoki","year":"1979","journal-title":"J Clin Invest."},{"key":"B91","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1046\/j.1365-2141.2001.02845.x","article-title":"Congenital alpha(2)-plasmin inhibitor deficiencies. a review","volume":"114","author":"Favier","year":"2001","journal-title":"Br J Haematol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.thromres.2018.04.006","article-title":"A novel allele variant of the SERPINF2 gene responsible for severe plasmin inhibitor (alpha2-antiplasmin) deficiency in an Italian patient","volume":"166","author":"Vigano","year":"2018","journal-title":"Thromb Res."},{"key":"B93","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0049-3848(96)00059-X","article-title":"Heterozygote for plasmin inhibitor deficiency developing hemorrhagic tendency with advancing age","volume":"82","author":"Ikematsu","year":"1996","journal-title":"Thromb Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1126\/science.2958938","article-title":"Alpha 2-antiplasmin Enschede: alanine insertion and abolition of plasmin inhibitory activity","volume":"238","author":"Holmes","year":"1987","journal-title":"Science."},{"key":"B95","first-page":"609","article-title":"Alpha 2-antiplasmin Enschede is not an inhibitor, but a substrate, of plasmin","volume":"255","author":"Rijken","year":"1988","journal-title":"Biochem J."},{"key":"B96","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1182\/blood-2010-01-263103","article-title":"Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men","volume":"116","author":"Meltzer","year":"2010","journal-title":"Blood."},{"key":"B97","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/0049-3848(79)90118-X","article-title":"alpha 2-Antiplasmin consumption and fibrinogen breakdown during thrombolytic therapy","volume":"14","author":"Collen","year":"1979","journal-title":"Thromb Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/S0735-1097(10)80003-8","article-title":"Plasmin inhibitors in the prevention of systemic effects during thrombolytic therapy: specific role of the plasminogen-binding form of alpha 2-antiplasmin","volume":"15","author":"Leebeek","year":"1990","journal-title":"J Am Coll Cardiol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/JCI116335","article-title":"Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis","volume":"91","author":"Weitz","year":"1993","journal-title":"J Clin Invest."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global burden of thrombosis. Epidemiologic Aspects","volume":"118","author":"Wendelboe","year":"2016","journal-title":"Circ Res."},{"key":"B101","doi-asserted-by":"publisher","first-page":"15006","DOI":"10.1038\/nrdp.2015.6","article-title":"Venous thrombosis","volume":"1","author":"Wolberg","year":"2015","journal-title":"Nat Rev Dis Primers."},{"key":"B102","first-page":"250","article-title":"Acceleration of plasma clot lysis by an antibody to alpha 2-antiplasmin","volume":"101","author":"Reed","year":"1988","journal-title":"Trans Assoc Am Physicians."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1182\/blood.V74.8.2692.2692","article-title":"Clot lysis induced by a monoclonal antibody against alpha 2-plasmin inhibitor","volume":"74","author":"Sakata","year":"1989","journal-title":"Blood."},{"key":"B104","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1046\/j.1538-7836.2003.00078.x","article-title":"Recombinant human microplasmin: production and potential therapeutic properties","volume":"1","author":"Nagai","year":"2003","journal-title":"J Thromb Haemost."},{"key":"B105","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1161\/01.STR.0000140628.00927.1a","article-title":"Microplasmin reduces ischemic brain damage and improves neurological function in a rat stroke model monitored with MRI","volume":"35","author":"Suzuki","year":"2004","journal-title":"Stroke."},{"key":"B106","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1161\/01.STR.0000028267.09604.7B","article-title":"Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits","volume":"33","author":"Lapchak","year":"2002","journal-title":"Stroke."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.clinthera.2009.08.019","article-title":"Neutralization of alpha(2)-antiplasmin by microplasmin: a randomized, double-blind, placebo-controlled, ascending-dose study in healthy male volunteers","volume":"31","author":"Pakola","year":"2009","journal-title":"Clin Ther."},{"key":"B108","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1161\/STROKEAHA.109.560201","article-title":"Randomized, placebo-controlled, dose-ranging clinical trial of intravenous microplasmin in patients with acute ischemic stroke","volume":"40","author":"Thijs","year":"2009","journal-title":"Stroke."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s40265-013-0124-1","article-title":"Ocriplasmin: a review of its use in patients with symptomatic vitreomacular adhesion","volume":"73","author":"Syed","year":"2013","journal-title":"Drugs."},{"key":"B110","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1538-7836.2009.03701.x","article-title":"Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential","volume":"8","author":"Marder","year":"2010","journal-title":"J Thromb Haemost."},{"key":"B111","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.tips.2003.12.009","article-title":"Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?","volume":"25","author":"Novokhatny","year":"2004","journal-title":"Trends Pharmacol Sci."},{"key":"B112","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1055\/s-0037-1616127","article-title":"Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit","volume":"86","author":"Marder","year":"2001","journal-title":"Thromb Haemost."},{"key":"B113","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1182\/blood-2002-08-2546","article-title":"Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage","volume":"101","author":"Stewart","year":"2003","journal-title":"Blood."},{"key":"B114","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/j.1538-7836.2012.04728.x","article-title":"Safety of catheter-delivered plasmin in patients with acute lower extremity arterial or bypass graft occlusion. phase I results","volume":"10","author":"Marder","year":"2012","journal-title":"J Thromb Haemost."},{"key":"B115","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.09.022","article-title":"Plasmin (human) administration in acute middle cerebral artery ischemic stroke. Phase 1\/2a, open-label, dose-escalation, safety study","volume":"26","author":"Mitchell","year":"2017","journal-title":"J Stroke Cerebrovasc Dis."},{"key":"B116","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.1021\/bi900257m","article-title":"Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design","volume":"48","author":"Lee","year":"2009","journal-title":"Biochemistry."},{"key":"B117","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1538-7836.2011.04195.x","article-title":"Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor alpha2-antiplasmin","volume":"9","author":"Lee","year":"2011","journal-title":"J Thromb Haemost."},{"key":"B118","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/0014-5793(83)80645-0","article-title":"Factor XIII-mediated cross-linking of NH2-terminal peptide of alpha 2-plasmin inhibitor to fibrin","volume":"153","author":"Ichinose","year":"1983","journal-title":"FEBS Lett."},{"key":"B119","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood.V66.1.157.157","article-title":"Acceleration of fibrinolysis by the N-terminal peptide of alpha 2-plasmin inhibitor","volume":"66","author":"Kimura","year":"1985","journal-title":"Blood."},{"key":"B120","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0049-3848(02)00030-0","article-title":"Effect of a synthetic carboxy-terminal peptide of alpha(2)-antiplasmin on urokinase-induced fibrinolysis","volume":"105","author":"Lee","year":"2002","journal-title":"Thromb Res."},{"key":"B121","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1472-6750-9-15","article-title":"Addition of a sequence from alpha2-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis","volume":"9","author":"Sheffield","year":"2009","journal-title":"BMC Biotechnol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2020.608899\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,18]],"date-time":"2021-04-18T04:38:00Z","timestamp":1618720680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2020.608899\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,23]]},"references-count":121,"alternative-id":["10.3389\/fcvm.2020.608899"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2020.608899","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,23]]},"article-number":"608899"}}